Ziritaxestat
Ziritaxestat (GLPG1690) is a small molecule autotaxin inhibitor. It has been investigated in a Phase 2 clinical trial for idiopathic pulmonary fibrosis (IPF) . Preclinical studies in vitro and in animal models have demonstrated its role in targeting the LPA pathway relevant to fibrotic diseases.
Product Specifications
CAS Number
1628260-79-6
Product Name Alternative
Autotaxin, Inhibitor, GLPG1690, GLPG-1690, GLPG 1690, inhibit, Ziritaxestat, Phosphodiesterase (PDE), phosphodiesterase
Field of Research
Metabolism Research
Purity
97.00% (May vary between batches)
Solubility
10% DMSO+40% PEG300+5% Tween 80+45% Saline:2 mg/mL (3.4 mM) ; DMSO:50 mg/mL (84.93 mM) ; H2O:< 0.1 mg/mL (insoluble)
Smiles
CCc1nc2c (C) cc (cn2c1CNc1nc (c (s1) C#N) -c1ccc (F) cc1) N1CCN (CC (=O) N2CC (O) C2) CC1
Molecular Formula
C30H33FN8O2S
Molecular Weight
588.7
Storage Conditions
-20°C
Notes
For research use only.
Available Sizes
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
PRG2 CRISPRa sgRNA lentivector (set of three targets)(Human)
Recombinant ZIKV Protein prM/prM Protein, N-GST & C-His
![Human CAMLG Matched Antibody Pair Set [ABP-Q-0403]](https://cdn.genprice.uk/genprice/uk/genprice4.webp)
Human CAMLG Matched Antibody Pair Set [ABP-Q-0403]